TMT vs Healthcare vs Consumer vs Industrials pros and cons

I am new to this forum and I am not sure if this has been discussed before. I am currently going through the SA recruiting process and was trying to figure out what sector/group to consider.
I would greatly appreciate if someone could list some pros and cons of working in the healthcare, TMT and consumer and industrials product group. Would like to hear your perspectives on deal flows, how the industry has changed over the past years and the greatest thing about working in those coverage groups.
Thanks

 

A lot will be firm specific and depends on what subsectors your firm is strong in. Look at wallstreetplayboys in the forum. M&I is a better resource than strangers in the comments.

Consumer-Pros: pretty steady deal flow, recognizable companies, lot of sponsor activity

Cons: I find it pretty boring, widespread industry consolidation, growth prospects are murky depending on the subsector.

Really a massive industry to generalize.

HC Pros: Biotech is pretty fuckin sexy, decent amount of m&a/IPOs in the whole sector, pharmacies are hot, diagnostics as well

Cons: outside biotech it may seem kinda dull, science background maybe necessary to really excel later in life/buyside.

Industrials/TMT-way too broad

 
Most Helpful

I can only speak for healthcare because that's my field.

Pros

  • There is a lot of activity and there will be in the next few years between M&A, divestments and other forms of business deals

  • Therapy markets are growing. It seems like a horrible thing to say but for healthcare it's a good thing if more people get sick because it means more sales or more incentives to produce better R&D products

  • Biotech is fucking sexy as mentioned above and new technologies such as gene therapies, viral vectors and advanced delivery methods make the field always interesting

  • Markets shift based on their diseases; as lesser developed markets grow they transition from having a big infectious disease problem to age-related issues which also leads to new strategies and tactics to develop

  • Everyone can have a bite at the pie. IP lawyers love healthcare as there is always a lot to do, economists can work on pricing models and deal with national or continental pricing agreements, bankers can work on financing deals, consultants work on strategy plays and PE/VC firms help new start-ups grow significantly.

  • There is little to no stagnation in the market. Unlike other markets which are pretty consolidated (commercial airlines, smartphones, Tobacco e.t.c) pharma has thousands of companies and even the big ones aren't in an oligopoly. The market is always buying or splitting up firms which means activity for all (similar to point 1)

Cons

  • Some areas of the field can be boring. This is a personal opinion but I've done some projects with old people's homes and hospitals - these are perhaps the least sexy parts of healthcare but then again all fields have their boring parts

  • The field is very technical and will continue to be so as technology gets more complex. No one will take you seriously if you don't have at least a BSc in a biomedical science. Perhaps this wasn't true 10 years ago but it is now. It could also be more consulting-specific than healthcare IB but I've had clients ask shit along the lines of 'we would need a PA2 comparison for our orthosteric antagonist compared to others and see if any allosterics are on the horizon'. Some people will drop hard science on you fast.

  • In some areas the maths gets complex fast such as pricing models, healthcare economics and insurances. I don't deal with those areas regularly but those projects tend to be very numerical and data heavy.

 

Incidunt id voluptates voluptate sequi. Blanditiis necessitatibus magnam et aut. Non iure consequuntur animi ratione distinctio. Iusto sit beatae fugiat. Ut at aliquid est velit voluptatem. Ducimus asperiores et possimus tenetur aut.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (87) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
Secyh62's picture
Secyh62
99.0
5
GameTheory's picture
GameTheory
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
kanon's picture
kanon
98.9
9
DrApeman's picture
DrApeman
98.8
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”